Wells Fargo & Company Transcode Therapeutics, Inc. Transaction History

Wells Fargo & Company

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.31 - $0.91 $0 - $0	1 Added 2.0%	51 $0
Q4 2022 Feb 13, 2023	BUY	$0.33 - $984.0 $0 - $984	1 Added 2.04%	50 $0
Q3 2022 Nov 14, 2022	BUY	$1.01 - $952.0 $4 - $3,808	4 Added 8.89%	49 $0
Q2 2022 Aug 12, 2022	BUY	$1.2 - $3.03 $4 - $12	4 Added 9.76%	45 $0
Q4 2021 Feb 14, 2022	BUY	$2.42 - $3.41 $7 - $10	3 Added 7.89%	41 $0
Q3 2021 Nov 15, 2021	BUY	$2.37 - $6.45 $90 - $245	38 New	38 $0

6.5K

Ticker RNAZ
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,977,200
Market Cap $6.1M
Description
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs incl...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.